AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy

Mark Cameron

Mark Cameron, PhD, a graduate of the University of Michigan and Eastern Michigan University. Mark has over 20 years of immunoassay design, development and commercialization experience including work done at the Cancer Center at the University of Michigan, Assay Designs, Inc., Cayman Chemical Company, MPI Research and Beckman Coulter. Mark introduced to the commercial marketplace or in to the GLP (Good Laboratory Practice) space more than 120 immunoassays including the first available ELISA to measure a phosphorylated protein, mitogen-activated protein kinase 3, also known as p-ERK. Mark has a wide range of biomarker, PK (pharmacokinetic) assay and immunogenicity development experience including colorimetric ELISA, Luminex, MSD, Gyros and SPARCL. During his career, Mark has acted as a Senior Scientist, Associate Director, and Senior Manager. Mark is widely published in journals such as Cancer Research, The Journal of Immunological Methods, Bioanalysis and The Proceedings of the National Academy of Sciences.